Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Abstract

The present application discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the application discloses the use of these compounds, a method for therapy and to pharmaceutical compositions comprising these compounds.

1 .- 15 . (canceled) 
     
     
         16 . A compound of Formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein R 1  represents methoxy. 
       
     
     
         17 . The compound according to  claim 16 , which is
 exo-7-[(-8-azabicyclo[3.2.1]octan-3-yl)oxy]-3-methoxy-chromen-2-one;   or a pharmaceutically acceptable salt thereof.   
     
     
         18 . The compound according to  claim 16 , which is exo-7-[(-8-azabicyclo[3.2.1]octan-3-yl)oxy]-3-methoxy-chromen-2-one hydrochloride. 
     
     
         19 . A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to  claim 16 , or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent. 
     
     
         20 . A method for treatment, prevention or alleviation of a disease or a disorder or a condition responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to  claim 16 , or a pharmaceutically acceptable salt thereof. 
     
     
         21 . The method according to  claim 20 , for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system. 
     
     
         22 . The method according to  claim 21 , wherein the disease, disorder or condition is pain, anxiety, depression or sexual dysfunction. 
     
     
         23 . The method according to  claim 22 , wherein the disease, disorder or condition is pain. 
     
     
         24 . The method according to  claim 22 , wherein the disease, disorder or condition is sexual dysfunction.